CytoTherapeutics, T Cell Sciences deal

TCEL licensed portions of its Complement Receptor 1 ( CR1) technology for use in CTII's cell-based products to deliver drugs to the central nervous system.

CTII received non-exclusive rights to CR1 for non-therapeutic use in any encapsulated-cell product, TCEL said. The agreement includes undisclosed signing, milestone and royalty payments. ...